Peptides for treating bone diseases and use thereof

Abstract

The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 16 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.

What is claimed is: 
     
       1. A method for treating a subject with osteoporosis, comprising:
 administering a peptide consisting of the amino acid sequence of SEQ ID NO: 1 in a therapeutically effective amount to the subject in need thereof. 
 
     
     
       2. The method of  claim 1 , wherein the peptide decreases the expression level of an adhesion factor for a bone marrow hematopoietic stem cell and mobilizes the bone marrow hematopoietic stem cell in bone marrow to bloodstream. 
     
     
       3. The method of  claim 1 , wherein the peptide decreases the number of osteoclasts in bone marrow of the subject.